Suchergebnisse - "Bylicki, Olivier"

PubPharm (10)

1

Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer

enthalten in: Journal of cancer research and clinical oncology | 2023

von Doubre, H. | Greillier, L. | Justeau, G. | +14

2

Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer : An open-label phase II trial (VinMetAtezo)

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2023

von Vergnenegre, A. | Monnet, I. | Ricordel, C. | +13

3

Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies : A multicentre phase II open-label non-randomised study GFPC 06-2018

enthalten in: European journal of cancer (Oxford, England : 1990) | 2023

von Bylicki, O. | Tomasini, P. | Radj, G. | +20

4

Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2022

von Justeau, G. | Huchot, E. | Simonneau, Y. | +15

5

Performances, feasibility and acceptability of nasopharyngeal swab, saliva and oral-self sampling swab for the detection of severe acute respiratory syndrome coronavirus 2

enthalten in: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology | 2021

von Plantamura, J. | Bousquet, A. | Otto, M. | +14

6

Feasibility of Stereotactic Body Radiation Therapy on Unresectable Stage III NSCLC with Peripheral Primary Tumor : A Prospective Study (GFPC 01-14)

enthalten in: Current oncology (Toronto, Ont.) | 2021

von Martel-Lafay, I. | Monnet, I. | Lardy-Cleaud, A. | +7

7

Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation : GFPC 01-2018

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2020

von Guisier, F. | Dubos-Arvis, C. | Viñas, F. | +15

CommentIn: J Thorac Oncol. 2020 Apr;15(4):489-492. - PMID 32216943

8

Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma

enthalten in: Medicine | 2020

von Bylicki, O. | Guisier, F. | Monnet, I. | +8

9

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2) : a multicentre, open-label, randomised, non-comparative, phase 2 trial

enthalten in: The Lancet. Oncology | 2019

von Scherpereel, A. | Mazieres, J. | Greillier, L. | +22

CommentIn: Lancet Oncol. 2019 Feb;20(2):172-174. - PMID 30660608

10

Assessing the multimodal management of advanced solitary fibrous tumors of the pleura in a routine practice setting

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2015

von Bylicki, O. | Rouvière, D. | Cassier, P. | +7

CommentIn: J Thorac Oncol. 2015 Jun;10(6):e53-4. - PMID 26001156

1
[1]